In an interview in Nordic Life Science, the Head of AstraZeneca’s Oncology Business unit, shared his insights on current drug development within oncology and how we can create faster access to innovative medicines. “Drug development within oncology has evolved to become more flexible,” said David Fredrickson, head of AstraZeneca’s oncology business unit. “Clinical trials with … Continue reading Exclusive R&D interview: David Fredrickson